3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Brain Neoplasms
133
Glioblastoma
92
Astrocytoma
44
Neuroblastoma
40
Glioma
40
Central Nervous System Neoplasms
38
Neoplasms
26
Breast Neoplasms
25
Neoplasm Metastasis
24
Oligodendroglioma
20
Gliosarcoma
19
Carcinoma, Non-Small-Cell Lung
18
Lymphoma, Follicular
14
Recurrence
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Medulloblastoma
13
Burkitt Lymphoma
13
Testicular Neoplasms
12
Lymphoma, T-Cell, Cutaneous
12
Lymphoma, Non-Hodgkin
12
Lymphoma, Mantle-Cell
12
Lymphoma, Large-Cell, Immunoblastic
12
Lymphoma, Large B-Cell, Diffuse
12
Lymphoma, B-Cell, Marginal Zone
12
Leukemia, Lymphocytic, Chronic, B-Cell
12
Hodgkin Disease
12
Sezary Syndrome
11
Primary Myelofibrosis
11
Mycosis Fungoides
11
Leukemia, Myeloid, Chronic-Phase
11
Interventions
brolucizumab
1
aflibercept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Macular Degeneration
×
CNS
×
Clear all
NCT03710564
2023-01-30
MERLIN
Novartis
Phase 3
Terminated
535 enrolled
14 charts